Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for.

Business Wire • Feb 20, 2026

Medifast Q4 Loss Wider Than Expected, Revenues Decline 37% Y/Y

MED posts a wider quarterly loss as revenue tumbles 36.9% on a sharp drop in OPTAVIA coaches, despite beating revenue estimates.

Zacks Investment Research • Feb 18, 2026

Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript

Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 17, 2026

Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valua.

Business Wire • Feb 17, 2026

Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates

Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.

Zacks Investment Research • Feb 17, 2026

Medifast's Q4 Earnings on Deck: What Could Shape MED's Results?

MED is likely to post a sharp Q4 revenue drop and a wider loss as active earning coaches decline and GLP-1 pressure weighs despite retention and pricing efforts.

Zacks Investment Research • Feb 13, 2026

Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for

Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 10, 2026

Medifast Is A Net-Net With Negative Enterprise Value

Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely obsolete, prompting a pivot toward metabolic health services, though execution risk remains high. Despite ongoing losses, MED's cash burn is modest; even with conservative assumptions, shares likely remain a net-net with limited downside over the next year.

Seeking Alpha • Feb 4, 2026

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney.

Business Wire • Feb 3, 2026

Medifast's Q4 Guidance Remains Weak: When Does Growth Return?

MED sees weak Q4 guidance after steep revenue declines, but a metabolic health pivot targets stabilization and recovery.

Zacks Investment Research • Jan 22, 2026